Modalis Therapeutics Corporation announced it will regain full development and commercial rights to MDL-201 and MDL-202 from Astellas Pharma Inc. It also reveals that target indications for the products are Duchene Muscular Dystrophy (DMD) and Myotonic Dystrophy type 1 (DM1), respectively. Modalis is also announcing a sharpened strategic focus, to prioritize its investments in the most promising programs: MDL-101, the lead program in its pipeline which has completed preIND and is moving forward to the clinic for LAMA2-CMD, and MDL-202 for DM1. This matter shall have a minor impact on cost compared with that of the whole R&D for the fiscal year ending December 31, 2023, and the following years.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
79 JPY | 0.00% | +2.60% | -36.29% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,552 JPY | -0.42% | +2.48% | 18.27B | ||
79 JPY | 0.00% | +2.60% | 17.67M | ||
1st Jan change | Capi. | |
---|---|---|
-36.29% | 17.67M | |
+9.15% | 105B | |
-1.08% | 104B | |
+5.79% | 22.94B | |
-11.55% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-9.91% | 16.96B | |
+7.55% | 14.16B | |
+40.04% | 12.63B |
- Stock Market
- Equities
- 4883 Stock
- News Modalis Therapeutics Corporation
- Modalis Therapeutics Corporation to Regain Full Rights to MDL-201 and MDL-202 from Astellas Pharma Inc